Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in NTLA.
← Back to Free Index

NTLA

Analysis as of: 2026-07-07
Intellia Therapeutics, Inc.
Clinical-stage biotechnology company developing one-time CRISPR-based gene-editing medicines for hereditary angioedema, transthyretin amyloidosis, and other severe diseases.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical Proof Nears a Commercial Test
The core question is whether the first strong in vivo CRISPR Phase 3 result becomes a clean filing, approval and rare-disease launch. If that conversion works, the business can move from platform option value to a real franchise; if not, the rerating stalls.

Analysis

Thesis
NTLA can rerate from a cash-burning gene-editing platform into a real rare-disease franchise if lonvo-z converts Phase 3 proof into approval, payer access and a 2027 launch, while nex-z restores second-asset credibility by 2031; the non-linear upside comes from first-mover trust, reusable human data and one-time therapy economics, not from AI alone.
Last Economy Alignment
Low software commoditization risk and real human-data/IP flywheels help, but FDA trust, CMC execution and reimbursement still determine whether cheaper cognition becomes durable value.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.1x (from 5 most recent analyses)
Reasoning
I underwrite a category change from development-stage platform to launched orphan-franchise, with lonvo-z doing most of the work and ATTR adding option value. That deserves a healthy commercial biotech multiple, but not a full platform premium, because revenue concentration, first-launch risk and FDA gating remain material.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
This is now a regulatory-and-launch conversion story more than a pure science story. The upside is large if lonvo-z becomes an approved, reimbursed one-time therapy, but the path is narrow: BLA completeness, FDA review, CMC reliability, payer contracting and ATTR re-validation all have to line up before platform value broadens.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.31
They control rare human editing data and are close to a valuable trust checkpoint: turning gene-editing science into an approved medicine. AI can help design better drugs, but it does not remove the hard parts here, because FDA trust, manufacturing reliability and long-term safety still control the pace of value creation.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$26.33
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case